New molecular targets and biological therapies in sarcomas
Related Experiment Video
Updated: Oct 2, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
1Department of Pathology, Stanford University Medical Center, 269 Campus Drive, CCSR 3220, Stanford, CA 94305, USA. anthon@leland.stanford.edu
Abstract:
The treatment of patients with soft tissue and bone sarcomas has dramatically improved over the last decade. This improvement has been brought about through advances in diagnosis, surgical techniques, conformal radiotherapy, and combination chemotherapy. Further advances in the management of the diverse spectrum of sarcoma patients will reflect tailoring of therapy based on molecular abnormalities. The role of cytogenetics and molecular analysis of fusion or mutated genes in diagnosis, prognosis, and design of biological treatments is discussed. An example of this approach has been the recent success in treatment of patients with gastrointestinal stromal tumours expressing mutant c-kit with a specific tyrosine kinase inhibitor, STI571. Molecular rearrangements may also serve as targets for designing specific immunotherapies with the fusion gene product. The use of biological therapies with signal transduction inhibitors, angiogenesis inhibitors, matrix metalloproteinase inhibitors, immunotherapy, differentiation inducers, and gene therapy could complement existing treatments for long-term control of disease. As these newer biological agents take form, clinical trial design will undergo change to reflect the chronic nature of these therapies.
Insights
Advances in sarcoma treatment, including molecular analysis, are improving patient outcomes. Tailoring therapies based on genetic abnormalities offers new hope for managing these diverse cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Soft tissue and bone sarcoma treatment has significantly improved due to advances in diagnosis, surgery, radiotherapy, and chemotherapy.
- Future progress hinges on personalized therapy guided by molecular abnormalities.
Purpose of the Study:
- To discuss the role of cytogenetics and molecular analysis in sarcoma diagnosis, prognosis, and biological treatment design.
- To highlight the potential of novel biological therapies for long-term disease control.
Main Methods:
- Review of current treatment modalities and their improvements.
- Analysis of molecular abnormalities, including fusion or mutated genes.
- Discussion of emerging biological therapies and their mechanisms.
Main Results:
- Cytogenetics and molecular analysis are crucial for diagnosis and prognosis.
- Targeted therapies, like tyrosine kinase inhibitors for c-kit mutated gastrointestinal stromal tumors, show success.
- Molecular rearrangements can be targets for immunotherapy.
Conclusions:
- Personalized therapy based on molecular profiling is key to advancing sarcoma management.
- Novel biological agents, including signal transduction inhibitors and gene therapy, offer potential for long-term disease control.
- Clinical trial designs need to adapt to the chronic nature of these new therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...